Breaking Finance News

Merus Labs International Inc (USA) (NASDAQ:MSLI) has been downgraded to Strong Sell in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Merus Labs International Inc (USA)(NASDAQ:MSLI) to Strong Sell in a report released on 8/17/2016.

Boasting a price of $1.01, Merus Labs International Inc (USA) (NASDAQ:MSLI) traded 0.91% higher on the day. The last close is down 23.46% from the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time. Merus Labs International Inc (USA) has been tracking to a 50-day moving average of $1.09 and 200-day average of $1.31. 32,036 shares of the stock traded hands, up from ann average trading volume of 26,311

Performance Chart:

Merus Labs International Inc (USA) (NASDAQ:MSLI)

With a market capitalization of $0.0, Merus Labs International Inc (USA) has a 52 week low of $0.92 and a one-year high of $1.90 with a PE ratio of 0.

Brief Synopsis On Merus Labs International Inc (USA) (NASDAQ:MSLI)

Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives. Its products include Factive and Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *